OVID PE Ratio & Valuation,Is OVID Overvalued

OVID Relative Valuation

OVID's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OVID is overvalued; if below, it's undervalued.

Historical Valuation

Ovid Therapeutics Inc (OVID) is now in the Overvalued zone, suggesting that its current forward PS ratio of 615.97 is considered Overvalued compared with the five-year average of -3.21. The fair price of Ovid Therapeutics Inc (OVID) is between 0.09 to 0.90 according to relative valuation methord. Compared to the current price of 1.56 USD , Ovid Therapeutics Inc is Overvalued By 74.12%.

Relative Value

Fair Zone

0.09-0.90

Current Price：1.56

74.12%

Overvalued

-3.50

0.00

EV/EBITDA

Ovid Therapeutics Inc. (OVID) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.36. The thresholds are as follows: Strongly Undervalued below -11.67, Undervalued between -11.67 and -5.65, Fairly Valued between 6.38 and -5.65, Overvalued between 6.38 and 12.40, and Strongly Overvalued above 12.40. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-2.02

EV/EBIT

Ovid Therapeutics Inc. (OVID) has a current EV/EBIT of -2.02. The 5-year average EV/EBIT is -0.96. The thresholds are as follows: Strongly Undervalued below -3.51, Undervalued between -3.51 and -2.24, Fairly Valued between 0.31 and -2.24, Overvalued between 0.31 and 1.59, and Strongly Overvalued above 1.59. The current Forward EV/EBIT of -2.02 falls within the Historic Trend Line -Fairly Valued range.

615.97

Ovid Therapeutics Inc. (OVID) has a current PS of 615.97. The 5-year average PS is 316.32. The thresholds are as follows: Strongly Undervalued below -781.81, Undervalued between -781.81 and -232.75, Fairly Valued between 865.38 and -232.75, Overvalued between 865.38 and 1414.44, and Strongly Overvalued above 1414.44. The current Forward PS of 615.97 falls within the Historic Trend Line -Fairly Valued range.

-2.39

P/OCF

Ovid Therapeutics Inc. (OVID) has a current P/OCF of -2.39. The 5-year average P/OCF is -2.47. The thresholds are as follows: Strongly Undervalued below -9.34, Undervalued between -9.34 and -5.91, Fairly Valued between 0.97 and -5.91, Overvalued between 0.97 and 4.40, and Strongly Overvalued above 4.40. The current Forward P/OCF of -2.39 falls within the Historic Trend Line -Fairly Valued range.

-2.28

P/FCF

Ovid Therapeutics Inc. (OVID) has a current P/FCF of -2.28. The 5-year average P/FCF is -0.48. The thresholds are as follows: Strongly Undervalued below -5.66, Undervalued between -5.66 and -3.07, Fairly Valued between 2.11 and -3.07, Overvalued between 2.11 and 4.70, and Strongly Overvalued above 4.70. The current Forward P/FCF of -2.28 falls within the Historic Trend Line -Fairly Valued range.

Ovid Therapeutics Inc (OVID) has a current Price-to-Book (P/B) ratio of 2.62. Compared to its 3-year average P/B ratio of 1.61 , the current P/B ratio is approximately 62.89% higher. Relative to its 5-year average P/B ratio of 1.60, the current P/B ratio is about 63.32% higher. Ovid Therapeutics Inc (OVID) has a Forward Free Cash Flow (FCF) yield of approximately -32.50%. Compared to its 3-year average FCF yield of -65.31%, the current FCF yield is approximately -50.24% lower. Relative to its 5-year average FCF yield of -36.17% , the current FCF yield is about -10.15% lower.

2.50

P/B

Median3y

1.61

Median5y

1.60

-32.50

FCF Yield

Median3y

-65.31

Median5y

-36.17

Competitors Valuation Multiple

The average P/S ratio for OVID's competitors is 0.00, providing a benchmark for relative valuation. Ovid Therapeutics Inc Corp (OVID) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -23.70%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of OVID increased by 67.08% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.76 to -3.11.

The secondary factor is the Margin Expansion, contributed 13.77%to the performance.

Overall, the performance of OVID in the past 1 year is driven by P/E Change. Which is more unsustainable.

-23.70%

173.00K → 132.00K

Revenue Growth

13.77%

-8.10K → -9.21K

Margin Expansion

77.01%

-1.76 → -3.11

P/E Change

67.08%

0.93 → 1.56

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Ovid Therapeutics Inc (OVID) currently overvalued or undervalued?

What is Ovid Therapeutics Inc (OVID) fair value?

OVID's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Ovid Therapeutics Inc (OVID) is between 0.09 to 0.90 according to relative valuation methord.

How does OVID's valuation metrics compare to the industry average?

What is the current P/B ratio for Ovid Therapeutics Inc (OVID) as of Dec 16 2025?

As of Dec 16 2025, Ovid Therapeutics Inc (OVID) has a P/B ratio of 2.62. This indicates that the market values OVID at 2.62 times its book value.

What is the current FCF Yield for Ovid Therapeutics Inc (OVID) as of Dec 16 2025?

As of Dec 16 2025, Ovid Therapeutics Inc (OVID) has a FCF Yield of -32.50%. This means that for every dollar of Ovid Therapeutics Inc’s market capitalization, the company generates -32.50 cents in free cash flow.

What is the current Forward P/E ratio for Ovid Therapeutics Inc (OVID) as of Dec 16 2025?

As of Dec 16 2025, Ovid Therapeutics Inc (OVID) has a Forward P/E ratio of -3.66. This means the market is willing to pay $-3.66 for every dollar of Ovid Therapeutics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Ovid Therapeutics Inc (OVID) as of Dec 16 2025?

As of Dec 16 2025, Ovid Therapeutics Inc (OVID) has a Forward P/S ratio of 615.97. This means the market is valuing OVID at $615.97 for every dollar of expected revenue over the next 12 months.

OVID Valuation